Hofseth Biocare ASA: Annual General Meeting completed
10 mai 2024 08h30 HE
|
Hofseth Biocare ASA
Hofseth BioCare ASA held its Annual General Meeting on 10 May 2024. 270,174,810 shares, amounting to 68.38 per cent of the share capital, were represent in the meeting or by proxy. All proposals were...
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024
19 avr. 2024 07h00 HE
|
Hofseth Biocare ASA
The Annual General Meeting of Hofseth BioCare ASA for 2024 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 10 May 2024 at 13:00 CET. The notice of the Annual...
Hofseth Biocare ASA: HBC ANNUAL REPORT 2023
19 avr. 2024 02h00 HE
|
Hofseth Biocare ASA
The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2023 and the Company has today published the Annual Report and Sustainability Report for 2023. Please...
Hofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING
05 avr. 2024 12h08 HE
|
Hofseth Biocare ASA
Today, 5 April 2024, funds managed by Bonafide (Bonafide Global Fish Fund, Bonafide Best Catches I, HBC I, and HBC II) have purchased approx. 7.1 million shares in Hofseth BioCare ASA (“HBC”),...
Hofseth Biocare ASA: UPDATED COMPANY PRESENTATION
21 mars 2024 05h40 HE
|
Hofseth Biocare ASA
Please find the HBC Company Presentation attached. For further information, please contact: James Berger, Chief Commercial Officer of Hofseth BioCare ASA Phone: +41 79 950 10 34 E-mail:...
Hofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN
14 mars 2024 07h12 HE
|
Hofseth Biocare ASA
Kristin Fjellby Grung, Chair of the Board of Hofseth BioCare ASA, has informed the Board of Directors that she will resign from the position on 31 March 2024, as she will assume a position as judge in...
Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT
09 févr. 2024 02h00 HE
|
Hofseth Biocare ASA
HBC had gross operating revenues of NOK 47.4m (33.6m) in the fourth quarter and NOK 218.5m (120.4m) for the full year. Adjusted for the sale of assets in the second quarter, operating revenues were...
Hofseth Biocare ASA: HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tumour activity
06 févr. 2024 09h56 HE
|
Hofseth Biocare ASA
HBC Immunology Inc. (70.6% owned by Hofseth BioCare ASA) reports today the successful completion of the first in vivo study within its prostate cancer development program. The study assessed whether...
Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
09 janv. 2024 06h44 HE
|
Hofseth Biocare ASA
Reference is made to the stock exchange announcement on 4 January 2024 regarding the conclusion of an extraordinary general meeting in Hofseth Biocare ASA ("HBC" or the "Company") whereby the general...
Hofseth Biocare ASA: EXTRAORDINARY GENERAL MEETING CONCLUDED
04 janv. 2024 08h02 HE
|
Hofseth Biocare ASA
Hofseth Biocare ASA ("HBC" or the "Company") has today, on 4 January 2024, completed an extraordinary general meeting. All items proposed on the agenda were adopted, including the share capital...